Tag: Immunotherapeutics
OSE Immunotherapeutics announces the appointment of Alexandre Lebeaut as independent director – 02/18/2022 at 18:00
Nantes, France – February 18, 2022, 6:00 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the appointment of Alexandre Lebeaut by cooptation as independent director of the Company*.…
OSE Immunotherapeutics co-opts Alexandre Lebeaut as independent director – 2022-02-18 at 18:15
(AOF) – OSE Immunotherapeutics has announced the appointment of Alexandre Lebeaut by cooptation as independent director of the Company. A doctor of medicine, Alexandre Lebeaut has more than 25 years…
OSE Immunotherapeutics is pleased to announce FDA Fast Track Designation for CD28 antagonist VEL-101/FR104, granted by Veloxis Pharmaceuticals, Inc., its partner in transplantation – 02/17/2022 18:00
Nantes, France – February 17, 2022, 6:00 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that Veloxis Pharmaceuticals, Inc., a subsidiary of Asahi Kasei, has obtained “Fast Track”…
OSE Immunotherapeutics Receives First Grant of Patent for Use of Tedopi® After Failure of PD-1 or PD-L1 Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients – 25 /01/2022 at 6:30 PM
A grant agreement issued by the Japanese Patent Office This new patent will protect Tedopi® until 2037 Nantes, France – January 25, 2022, 6:30 p.m. – OSE Immunotherapeutics SA (ISIN:…
OSE Immunotherapeutics announces the appointment of Dominique Costantini as interim Chief Executive Officer following the departure of Alexis Peyroles – 01/17/2022 at 07:30
Nantes, France – January 17, 2022, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the departure of Alexis Peyroles as Chief Executive Officer of the Company. Dominique…
OSE Immunotherapeutics: appointment of Dominique Costantini as Chief Executive Officer – 01/17/2022 at 08:18
(AOF) – OSE Immunotherapeutics has announced the departure of Alexis Peyroles as CEO of the company. Dominique Costantini, currently Chair of the OSE Immunotherapeutics Board of Directors and Chief Executive…
OSE Immunotherapeutics: Degroof Petercam on Purchase – 01/10/2022 at 09:50
(AOF) – Degroof Petercam started the coverage of OSE Immunotherapeutics with a Purchase recommendation and a price target of 15.52 euros due in particular to the potential of its cancer…
OSE Immunotherapeutics strengthens its management team with the appointment of Laurence de Schoulepnikoff as Chief Business Officer – 12/20/2021 at 6:00 p.m.
Three directors with senior profiles also come to support the key drug development team. Nantes, France – December 20, 2021, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)…